Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$60.97

-1.05 (-1.69%)

08:00
12/07/17
12/07
08:00
12/07/17
08:00

Bristol Myers Squibb put buyer realizes 44% same-day gains

Notable profits for the buyer who lifted the $0.82 offer for 1,499 Bristol Myers Squibb (BMY) 12/8 weekly 61.5 puts yesterday at 11:49ET when underlying shares were trading at $61.34. Shares closed at $60.97, and the puts at $1.17 for a mark-to-market profit of 44%, or $53K, on the $122K outlay.

  • 07

    Dec

  • 09

    Dec

  • 18

    Jan

  • 05

    Mar

BMY Bristol-Myers
$60.97

-1.05 (-1.69%)

11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$28.00

-2.82 (-9.15%)

07:33
11/21/18
11/21
07:33
11/21/18
07:33
Conference/Events
Mallinckrodt management to meet with Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 02

    Dec

QADA

Qad Inc.

$39.80

-0.31 (-0.77%)

07:33
11/21/18
11/21
07:33
11/21/18
07:33
Recommendations
Qad Inc. analyst commentary  »

Qad Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

07:31
11/21/18
11/21
07:31
11/21/18
07:31
Periodicals
Nissan seeks to weaken Renault influence, Reuters reports »

Japan said it is prepared…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMHC

Taylor Morrison

$16.00

-0.03 (-0.19%)

07:31
11/21/18
11/21
07:31
11/21/18
07:31
Hot Stocks
Taylor Morrison extends and increases stock repurchase program »

Taylor Morrison has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.97

-3.12 (-2.29%)

07:31
11/21/18
11/21
07:31
11/21/18
07:31
Conference/Events
IPG Photonics management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 17

    Dec

HOLX

Hologic

$41.29

-0.29 (-0.70%)

07:31
11/21/18
11/21
07:31
11/21/18
07:31
Conference/Events
Hologic management to meet with William Blair »

Meeting to be in Chicago…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 30

    Nov

07:30
11/21/18
11/21
07:30
11/21/18
07:30
General news
European stock markets broadly higher, »

European stock markets…

KSS

Kohl's

$64.45

-6.3 (-8.90%)

07:29
11/21/18
11/21
07:29
11/21/18
07:29
Recommendations
Kohl's analyst commentary  »

Kohl's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLC

Taiwan Liposome

$0.00

(0.00%)

07:28
11/21/18
11/21
07:28
11/21/18
07:28
Syndicate
Taiwan Liposome 3.75M share Secondary priced at $5.80 »

The deal size was cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KSS

Kohl's

$64.45

-6.3 (-8.90%)

07:28
11/21/18
11/21
07:28
11/21/18
07:28
Recommendations
Kohl's analyst commentary  »

Kohl's faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$183.74

-2.95 (-1.58%)

07:26
11/21/18
11/21
07:26
11/21/18
07:26
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.23

-0.54 (-5.53%)

, DNSKY

Danske Bank

$0.00

(0.00%)

07:25
11/21/18
11/21
07:25
11/21/18
07:25
Periodicals
Deutsche exec says bank had limited need to know of Danske details, Reuters says »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$9.23

-0.54 (-5.53%)

DNSKY

Danske Bank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.10

-8.7 (-4.68%)

07:23
11/21/18
11/21
07:23
11/21/18
07:23
Periodicals
Foxconn, biggest iPhone assembler, cutting expenses and jobs, Bloomberg reports »

Foxconn Technology Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

RP

RealPage

$45.77

0.17 (0.37%)

07:23
11/21/18
11/21
07:23
11/21/18
07:23
Upgrade
RealPage rating change  »

RealPage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, NKE

Nike

$71.13

-1.39 (-1.92%)

07:23
11/21/18
11/21
07:23
11/21/18
07:23
Recommendations
Foot Locker, Nike analyst commentary  »

Foot Locker price target…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

NKE

Nike

$71.13

-1.39 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

HNI

HNI Corporation

$36.97

-1.35 (-3.52%)

07:21
11/21/18
11/21
07:21
11/21/18
07:21
Conference/Events
HNI Corporation management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

HMST

HomeStreet

$25.24

-0.6 (-2.32%)

07:20
11/21/18
11/21
07:20
11/21/18
07:20
Conference/Events
HomeStreet management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AMZN

Amazon.com

$1,495.60

-16.07 (-1.06%)

07:20
11/21/18
11/21
07:20
11/21/18
07:20
Periodicals
Amazon opens Spanish pop-up store, Reuters reports »

Amazon opened its first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

07:20
11/21/18
11/21
07:20
11/21/18
07:20
General news
FX Update: The Dollar has traded mixed »

FX Update: The Dollar has…

WIX

Wix.com

$86.16

1.13 (1.33%)

07:19
11/21/18
11/21
07:19
11/21/18
07:19
Upgrade
Wix.com rating change  »

Wix.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$156.08

-4.16 (-2.60%)

07:17
11/21/18
11/21
07:17
11/21/18
07:17
Downgrade
Ecolab rating change  »

Oppenheimer downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

CMCM

Cheetah Mobile

$8.54

-0.22 (-2.51%)

07:17
11/21/18
11/21
07:17
11/21/18
07:17
Earnings
Breaking Earnings news story on Cheetah Mobile »

Cheetah Mobile sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CMCM

Cheetah Mobile

$8.54

-0.22 (-2.51%)

07:17
11/21/18
11/21
07:17
11/21/18
07:17
Earnings
Cheetah Mobile reports Q3 non-GAAP EPS 19c, consensus 17c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NVDA

Nvidia

$149.14

4.48 (3.10%)

07:16
11/21/18
11/21
07:16
11/21/18
07:16
Periodicals
Nvidia to provide AI platform for Chinese EV startups, Reuters reports »

Nvidia has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

HCSG

Healthcare Services

$44.20

0.31 (0.71%)

07:16
11/21/18
11/21
07:16
11/21/18
07:16
Conference/Events
Healthcare Services management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.